Abstracts Archive - Page 1328 of 2607 - ACR Meeting Abstracts

Abstract Number: 2126 • 2018 ACR/ARHP Annual Meeting
STAT4 Activation By Type I Interferons Regulates Pathogenic IL-21 and IFN-γ in Lupus
Xuemei Dong¹, Fotios Koumpouras², Joseph E. Craft³ and Jason Weinstein¹, ¹Rheumatology, Yale University School of Medicine, New Haven, CT, ²Internal Medicine, Rheumatology, Yale University School of Medicine, New Haven, CT, ³Department of Internal Medicine/Rheumatology, Yale University School of Medicine, New Haven, CT
Background/Purpose: Follicular helper T cells (Tfh) cells in lupus help shape the germinal center (GC) response by delivering contact-dependent and soluble signals, including the cytokines…
Abstract Number: 2127 • 2018 ACR/ARHP Annual Meeting
A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in Lupus Nephritis
Ioannis Parodis^1,2, Sirisha Gokaraju³, Agneta Zickert^1,2, Ting Zhang³, Deena Habazi³, Anders Larsson⁴, Elisabet Svenungsson^1,2, Chandra Mohan³ and Iva Gunnarsson^1,2, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Department of Biomedical Engineering, University of Houston, Houston, Texas, USA, Houston, TX, ⁴Department of Medical Sciences/Clinical Chemistry, Uppsala University, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose: Reliable non-invasive biomarkers for lupus nephritis (LN) are lacking. We investigated two adhesion molecules as urinary biomarkers in LN, i.e. vascular cell adhesion molecule…
Abstract Number: 2128 • 2018 ACR/ARHP Annual Meeting
The Effect of miRNA-21 Overexpression on the Aberrant T Follicular Helper Cells Differentiation in Systemic Lupus Erythematosus
Ming Zhao¹, Xiaofei Gao², Jiali Wu³, Limin Liu¹, Haijing Wu² and Qianjin Lu¹, ¹Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China, ²The Second Xiangya Hospital of Central South University, Changsha, China, ³Department of Deramtology, The Second Xiangya Hospital of Central South University, Changsha, China
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by a large number of autoantibodies and multiple organs damage. T follicular helper(Tfh)…
Abstract Number: 2129 • 2018 ACR/ARHP Annual Meeting
Precipitating Anti-dsDNA Peptide Repertoires in Lupus
Jing Jing Wang¹, Alexander Colella¹, Dimitra Beroukas², Tim Chataway³ and Tom Gordon^1,4, ¹Immunology, Flinders University, Adelaide, Australia, ²Immunology, SA Pathology, Adelaide, AR, Australia, ³Proteomic Facility, Flinders University, Adelaide, Australia, ⁴Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Anti-double-stranded (ds)DNA autoantibodies are prototypic serological markers of systemic lupus erythematosus (SLE) but little is known about their immunoglobulin variable (IgV) region composition at…
Abstract Number: 2130 • 2018 ACR/ARHP Annual Meeting
Interferon Induced Gene Transcripts Are Differentially Upregulated in the Kidney of Lupus Nephritis Patients Irrespective of Activity or Damage
S. Sam Lim¹, Alton B Farris¹, Tobias Guennel², Shiliang Wang³, Jason Cobb¹, Dominic Sinibaldi⁴, Scott Jenks¹, Ignacio Sanz¹, Xiang Guo³, Gabor Illei⁵, Kui Shen², Monica Battle¹, Chungwen Wei¹ and WI White³, ¹Emory University School of Medicine, Atlanta, GA, ²Precision for Medicine, Frederick, MD, ³MedImmune, Gaithersburg, MD, ⁴MedImmune, Gaithersberg, MD, ⁵Viela Bio, Gaithersburg, USA, Gaithersberg, MD
Background/Purpose: Lupus nephritis (LN) afflicts 12-69% lupus patients. Even with the best available therapies, complete response is achieved in only 10-85% of patients. The risk…
Abstract Number: 2131 • 2018 ACR/ARHP Annual Meeting
Prevalence of Systemic Lupus Erythematosus (SLE) and Associated Comorbidities in the 2011-2015 Medicare Population
Suying Li, Tingting Gong, Yi Peng, Kimberly M. Nieman and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN
Background/Purpose: Prevalence of systemic lupus erythematosus (SLE) has been estimated in different US regions. An estimate based on the 2005 US population showed SLE affecting…
Abstract Number: 2132 • 2018 ACR/ARHP Annual Meeting
All-Cause Mortality, Hospitalization, and Systemic Lupus Erythematosus (SLE) Related Complications in 2011-2015 Medicare Beneficiaries with SLE
Suying Li, Yi Peng, Tingting Gong, Kimberly M. Nieman and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at higher risk of complications such as heart attack and renal disease. We aimed to estimate all-cause…
Abstract Number: 2133 • 2018 ACR/ARHP Annual Meeting
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Hyungjoo Kang², Yujin Park⁴ and Jeffrey Greenberg^2,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are 3 common inflammatory rheumatic diseases that can lead to deformities and joint destruction;…
Abstract Number: 2134 • 2018 ACR/ARHP Annual Meeting
Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis
Amelia Green^1,2, Gavin Shaddick³, Rachel Charlton¹, Julia Snowball¹, Alison L Nightingale¹, Catherine Smith⁴, William Tillet^1,5 and Neil McHugh^1,5, ¹Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ²Department of Mathematical Sciences, The University of Bath, Bath, United Kingdom, ³Centre for Data Science and Statistics, The University of Exeter, Bath, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, St John’s Institute of Dermatology, London, United Kingdom, ⁵Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive and often destructive joint disease that causes pain, swelling and joint stiffness, and can lead to an impaired…
Abstract Number: 2135 • 2018 ACR/ARHP Annual Meeting
Identification of Psoriatic Arthritis Using an Administrative Claims-Based Algorithm
Julia Ford¹, Lindsey A. MacFarlane¹, Angela Tong² and Seoyoung C. Kim^1,3, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that can present variably in patients with or without psoriasis. The ability to accurately identify PsA…
Abstract Number: 2136 • 2018 ACR/ARHP Annual Meeting
Mortality Rates and Causes in Psoriatic Arthritis Patients
Ofir Elalouf¹, Anastasiya Muntyanu², Daniel Pereira¹, Ari Polachek³, Justine Y. Ye⁴, Ker-Ai Lee⁵, Vinod Chandran⁴, Richard J. Cook⁵ and Dafna D Gladman¹, ¹Rheumatology, Toronto Psoriatic Arthritis Research Program, University of Toronto, University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv Univrsity, Tel Aviv, Israel, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects about 30% of psoriasis patients, and can lead to significant joint damage and disability.…
Abstract Number: 2137 • 2018 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults
Cecilia Nalli¹, Greta Pascariello¹, Arianna Zentilin¹, Elena Raffetti², Laura Andreoli¹, Rajesh Kumar¹, Giuliana Martini³, Roberta Ottaviani¹, Cinzia Gasparotti⁴, Michele Magoni⁴, Carmelo Scarcella⁴, Francesco Donato⁵ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Epidemiology and Public Health Intervention Research group (EPHIR), Department of Public Health Sciences, Karolinska Institutet, Solna, Sweden, ³Hemostasis and Thrombosis Center, Spedali Civili of Brescia, Brescia, Italy, ⁴ATS Brescia (Brescia Health Protection Agency), Brescia, Italy, ⁵Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Unit of Hygiene, Epidemiology, and Public Health, University of Brescia, Italy., Brescia, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic autoimmune disease characterized by thrombotic and/or obstetrical manifestations mediated by antiphospholipid antibodies (aPL). By now, no population-based study…
Abstract Number: 2138 • 2018 ACR/ARHP Annual Meeting
Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis
Brian Ung¹, Dionne Hines², Sandhya Mehta¹, Corey Pelletier¹, Xin Wang² and Rolin Wade², ¹Celgene Corporation, Summit, NJ, ²IQVIA, Durham, NC
Background/Purpose: Methotrexate (MTX) is commonly used to treat psoriatic arthritis (PsA), yet data supporting its effectiveness in PsA are limited. This analysis describes real-world dosing,…
Abstract Number: 2139 • 2018 ACR/ARHP Annual Meeting
Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Mateo Mejia Saldarriaga¹, Ivan Emil Ramirez de Oleo¹ and Beverly Johnson^2,3, ¹Internal Medicine, Jacobi Medical Center, Bronx, NY, ²Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Glucose-6-phosphate dehydrogenase deficiency (G6PD) is linked to hemolytic anemia with certain medications and is the most common enzyme deficiency worldwide. Clinical hemolysis and severity…
Abstract Number: 2140 • 2018 ACR/ARHP Annual Meeting
Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Rheumatoid Arthritis: A Retrospective Study
Alisha Gupta¹, Aditya Joshi¹, Omar Saleem¹, Mary Chester-Wasko² and Tarun S. Sharma³, ¹Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA, ³Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ) is a derivative of quinidine, a class 1a anti-arrhythmic agent used to prevent ventricular arrhythmias and recurrent atrial fibrillation (AFib). AFib occurs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].